<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055845</url>
  </required_header>
  <id_info>
    <org_study_id>STA-01</org_study_id>
    <secondary_id>2015-004812-39</secondary_id>
    <nct_id>NCT03055845</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain</brief_title>
  <official_title>A Prospective, Randomised, Double-blinded, Placebo-controlled, Single Ascending Dose Study Investigating the Safety and Local Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stayble Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stayble Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I, randomized, double-blinded, placebo-controlled, single ascending dose study to&#xD;
      investigate the safety, local tolerability and transformation of nucleus pulposus following&#xD;
      intradiscal injection of STA363 or placebo in patients with discogenic low back pain.&#xD;
&#xD;
      15 patients will participate in either of 3 dose groups, each comprising 5 patients:&#xD;
&#xD;
        -  Group 1: STA363 dose 1 (3 patients) or placebo (2 patients)&#xD;
&#xD;
        -  Group 2: STA363 dose 2 (3 patients) or placebo (2 patients)&#xD;
&#xD;
        -  Group 3: STA363 dose 3 (3 patients) or placebo (2 patients)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following treatment of 2 patients in each dose group (injections with active drug and placebo, respectively), safety data will be reviewed. If no safety or tolerability concerns are identified, the next 3 patients in each dose group will be treated (active treatment or placebo [2:1]).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local injection site reactions</measure>
    <time_frame>Up to 4 weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Up to 12 weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in routine safety laboratory parameters</measure>
    <time_frame>Up to 12 weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analogue scale (VAS) pain (injection site)</measure>
    <time_frame>Up to 15 minutes after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vital signs</measure>
    <time_frame>Up to 12 weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in electrocardiogram (ECG)</measure>
    <time_frame>1 day after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in physical examination findings</measure>
    <time_frame>1 and 12 weeks after injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>12 weeks after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transformation of nucleus pulposus into connective tissue by magnetic resonance imaging (MRI)</measure>
    <time_frame>12 weeks after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disc height by MRI</measure>
    <time_frame>12 weeks after injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>VAS pain (leg and back)</measure>
    <time_frame>1, 4 and 12 weeks after injection</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Oswestry disability index (ODI) score</measure>
    <time_frame>12 weeks after injection</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>STA363 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>STA363 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>STA363 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA363</intervention_name>
    <description>STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.</description>
    <arm_group_label>STA363 dose 1</arm_group_label>
    <arm_group_label>STA363 dose 2</arm_group_label>
    <arm_group_label>STA363 dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to any study-related procedures&#xD;
&#xD;
          -  Chronic discogenic low back pain present for more than 6 months prior to the screening&#xD;
             visit&#xD;
&#xD;
          -  20 to 60 years of age at the screening visit&#xD;
&#xD;
          -  Insufficient response to at least 6 months of non-operative treatment (analgesics&#xD;
             and/or antiinflammatory medication, physiotherapy etc.)&#xD;
&#xD;
          -  A single lumbar disc appropriate for treatment at L3/4 to L5/S1, based on clinical&#xD;
             evaluation by the investigator&#xD;
&#xD;
          -  Pfirrmann grade II-III&#xD;
&#xD;
          -  Ability to understand the written and verbal information about the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any investigational product within 3 months prior to the screening&#xD;
             visit&#xD;
&#xD;
          -  More than one painful intervertebral disc&#xD;
&#xD;
          -  A painful intervertebral disc above L3/4 level&#xD;
&#xD;
          -  Current infection or prior history of spinal infection (e.g., discitis, septic&#xD;
             arthritis, epidural abscess) or an active systemic infection&#xD;
&#xD;
          -  Previous lumbar spine surgery&#xD;
&#xD;
          -  Previous disc invasive treatment procedures at the affected level(s) (e.g.,&#xD;
             intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation)&#xD;
&#xD;
          -  Pfirrmann grade I, IV and V&#xD;
&#xD;
          -  Evidence of prior lumbar vertebral body fracture or trauma&#xD;
&#xD;
          -  Need for spinal decompression assessed by the investigator&#xD;
&#xD;
          -  Presence of disc extrusion or sequestration&#xD;
&#xD;
          -  Patients previously included in the study&#xD;
&#xD;
          -  Patients suffering from psychosomatic pain in the opinion of the investigator&#xD;
&#xD;
          -  Referred leg pain of compressive origin&#xD;
&#xD;
          -  Known alcohol and/or drug abuse&#xD;
&#xD;
          -  Severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or&#xD;
             concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the&#xD;
             investigator, may put the patient at risk when participating in the study, or affect&#xD;
             the patient's ability to take part in the study&#xD;
&#xD;
          -  Clinically significant abnormalities in clinical chemistry or haematology parameters&#xD;
             as assessed by the investigator&#xD;
&#xD;
          -  Pregnant or lactating females or intention to become pregnant within the study period&#xD;
&#xD;
          -  Known allergy to any of the components of the drug product or placebo&#xD;
&#xD;
          -  Known opioid allergy or intolerance&#xD;
&#xD;
          -  Patients requiring treatment with warfarin or other anticoagulant therapy&#xD;
&#xD;
          -  Unwillingness to refrain from treatment with non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs) within 5 days before the planned study treatment&#xD;
&#xD;
          -  Body weight less than 50 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stockholm Spine Center, Löwenströmska Sjukhuset</name>
      <address>
        <city>Upplands Väsby</city>
        <zip>19489</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

